HEALY JAMES
SEC insider (Form 3/4/5 filer). CIK 0001245624. Director at BioAge Labs, Inc. (BIOA) and 4 other issuers. 20 reported Form 4/5 transactions since Sep 2024; latest on Jun 10, 2026. Located in BOSTON, MA.
Companies HEALY JAMES has filed insider reports for
- BioAge Labs, Inc. (BIOA): Director
- Rapport Therapeutics, Inc. (RAPP): Director
- Seaport Therapeutics, Inc. (SPTX): Director
- Y-mAbs Therapeutics, Inc. (YMAB): Director
- Natera, Inc. (NTRA): Director
HEALY JAMES
CIK: 0001245624
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Jun 10, 2026BIOA
BioAge Labs, Inc.
AwardDirectStock Option (Right to Buy)
22K shares- - Jun 10, 2026RAPP
Rapport Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
15.2K shares- - May 4, 2026SPTX
Seaport Therapeutics, Inc.
ConversionIndirect1.9M shares- - May 4, 2026SPTX
Seaport Therapeutics, Inc.
ConversionIndirect804.4K shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
DispositionDirect25.1K shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Tender OfferDirect31.6K shares at avg. $8.60$272K - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Tender OfferIndirect2.2M shares at avg. $8.60$18.9M - Jun 30, 2025YMAB
Y-mAbs Therapeutics, Inc.
AwardDirect25.1K shares- - Jun 17, 2025RAPP
Rapport Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
21.9K shares- - Jun 5, 2025BIOA
BioAge Labs, Inc.
AwardDirectStock Option (Right to Buy)
22K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  BIOA BioAge Labs, Inc. | Award Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Jun 10, 2026 |  RAPP Rapport Therapeutics, Inc. | Award Stock Option (Right to Buy) | 15,200 | - | - | Direct |
| May 4, 2026 |  SPTX Seaport Therapeutics, Inc. | Conversion | 1,927,159 | - | $0 | Indirect |
| May 4, 2026 | SPTX Seaport Therapeutics, Inc. | Conversion | 804,379 | - | $0 | Indirect |
| Sep 16, 2025 |  YMAB Y-mAbs Therapeutics, Inc. | Disposition | 25,080 | - | - | Direct |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Tender Offer | 31,603 | $8.60 | $271,786 | Direct |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Tender Offer | 2,194,278 | $8.60 | $18,870,791 | Indirect |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Award | 25,080 | - | - | Direct |
| Jun 17, 2025 | RAPP Rapport Therapeutics, Inc. | Award Stock Option (Right to Buy) | 21,850 | - | - | Direct |
| Jun 5, 2025 | BIOA BioAge Labs, Inc. | Award Stock Option (Right to Buy) | 22,000 | - | - | Direct |
1-10 of 20 transactions